Literature DB >> 28681207

Optimal Therapy of Advanced Stage Mesothelioma.

Maria M J Disselhorst1, Sjaak J A Burgers1, Paul Baas2.   

Abstract

OPINION STATEMENT: The optimal treatment of patients with advanced malignant pleural mesothelioma (MPM) has not yet been discovered. With the aid of an increased insight in the molecular pathways and the development of combinations of Immuno-Oncology (IO), drugs new therapies are available. The personalization of treatment by cell cultures and pathway analysis attracts more attention nowadays. It is conceivable that in the near future the treatment of patients with MPM will consist of a combination of IO drugs or specific pathway inhibitors.

Entities:  

Keywords:  Immuno-oncology drugs; Malignant pleural mesothelioma; Pathway inhibitors; Therapy

Mesh：

Year:  2017        PMID： 28681207     DOI： 10.1007/s11864-017-0488-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  26 in total

1.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Authors:  Hedy L Kindler; Theodore G Karrison; David R Gandara; Charles Lu; Lee M Krug; James P Stevenson; Pasi A Jänne; David I Quinn; Marianna N Koczywas; Julie R Brahmer; Kathy S Albain; David A Taber; Samuel G Armato; Nicholas J Vogelzang; Helen X Chen; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

Review 3.  The worldwide pandemic of asbestos-related diseases.

Authors:  Leslie Stayner; Laura S Welch; Richard Lemen
Journal:  Annu Rev Public Health       Date:  2013-01-04       Impact factor: 21.981

4.  Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

Authors:  Debby P M van den Bogaert; Ellen M Pouw; Gerda van Wijhe; René M Vernhout; Veerle F M Surmont; Henk C Hoogsteden; Rob J van Klaveren
Journal:  J Thorac Oncol       Date:  2006-01       Impact factor: 15.609

Review 5.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.

Authors:  Medhi Wangpaichitr; Chunjing Wu; Gregory Bigford; George Theodoropoulos; Min You; Ying Ying Li; Javier Verona-Santos; Lynn G Feun; Dao M Nguyen; Niramol Savaraj
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

Review 7.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

8.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Authors:  Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

9.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

10.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Authors:  Martin F Muers; Richard J Stephens; Patricia Fisher; Liz Darlison; Christopher M B Higgs; Erica Lowry; Andrew G Nicholson; Mary O'Brien; Michael Peake; Robin Rudd; Michael Snee; Jeremy Steele; David J Girling; Matthew Nankivell; Cheryl Pugh; Mahesh K B Parmar
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321
View more
  2 in total

1.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.

Authors:  Akihiro Matsushita; Tatsuhiro Sato; Satomi Mukai; Teruaki Fujishita; Emi Mishiro-Sato; Maho Okuda; Masahiro Aoki; Yoshinori Hasegawa; Yoshitaka Sekido
Journal:  Oncogene       Date:  2018-11-06       Impact factor: 9.867

2.  Current status of malignant mesothelioma with liver involvement in China: A brief report and review of the literature.

Authors:  Di Zhou; Zhiwei Quan; Jiandong Wang
Journal:  Intractable Rare Dis Res       Date:  2018-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.